Balanced news tone
News Sentiment
KMTS sentiment intelligence
Kestra Medical Technologies, Ltd. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-3.7% over one week, +24.7% over four weeks, trend inactive, and near fair-value range.
Kestra Medical Technologies (KMTS) Could Be 31% Overvalued As Earnings And 2027 Guidance Land
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Kestra Medical Technologies (KMTS) Could Be 31% Overvalued As Earnings And 2027 Guidance Land
Kestra Medical Technologies (KMTS) shares are under scrutiny after recent earnings, 2027 revenue guidance, and a new term loan facility. Despite a significant 1-year share price increase of 60.4%, the analysis suggests the company might be 31% overvalued, with a fair value estima
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 16 Jul 2026 00:12
- Source
- Simply Wall Street
Kestra Medical (NASDAQ: KMTS) investor Brian Webster plans 15,000-share sale
Brian Webster, an investor in Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), has filed a notice for the potential sale of 15,000 common shares valued at $336,609.41. These shares were initially acquired on January 1, 2026, through a restricted share issuance as part of the com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:12
- Source
- Stock Titan
Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 8.7% After Earnings Miss
Kestra Medical Technologies (NASDAQ:KMTS) saw its stock price fall 8.7% after reporting a quarterly EPS of -$0.67, missing analyst expectations. Despite the earnings miss, the company's revenue reached $28.64 million, and it secured a $200 million non-dilutive term loan facility
- Tone
- Negative 36/100
- Event
- Earnings
- Published
- 15 Jul 2026 14:12
- Source
- MarketBeat
Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Expected to Rise, BTIG Research Analyst Says
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 15 Jul 2026 12:32
- Source
- MarketBeat
Kestra Medical Technologies, Ltd. Stock 12‑Month Price Target Cut to $27.5, Implies 14% Upside
- Tone
- Negative 35/100
- Event
- Analyst action
- Published
- 15 Jul 2026 10:20
- Source
- TradingView
Kestra Medical Technologies, Ltd. Stock 12‑Month Price Target Raised to $28.43, Implies 18% Upside
Kestra Medical Technologies, Ltd. (KMTS) has seen its average 12-month price target increased from $27.71 to $28.43 by 7 analysts, suggesting an 18% potential upside from its July 14th closing price. The analyst consensus remains a "Buy," with 6 analysts recommending Buy and 1 re
- Tone
- Positive 75/100
- Event
- Analyst action
- Published
- 15 Jul 2026 10:12
- Source
- TradingView
Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue Growth ...
- Tone
- Positive 83/100
- Event
- Earnings
- Published
- 15 Jul 2026 05:00
- Source
- GuruFocus.com
Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 01:09
- Source
- The Motley Fool
Kestra Medical Technologies (KMTS) Reports Strong Q4 Fiscal 2026 Earnings
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 15 Jul 2026 00:02
- Source
- GuruFocus
Kestra Medical Technologies Q4 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 22:04
- Source
- MarketBeat
KESTRA MEDICAL TECHNOLOGIES ($KMTS) Releases Q4 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:30
- Source
- Quiver Quantitative
KESTRA MEDICAL TECHNOLOGIES, LTD. FY 2026: Revenue $95.1M, Net income $(131.6M) — 10-K Summary
Kestra Medical Technologies, Ltd. (KMTS) reported fiscal year 2026 revenue of $95.1 million, a 59% increase year-over-year, alongside a net loss of $(131.6) million, which widened from the previous year. The revenue growth was primarily driven by a 58% increase in patient volume
- Tone
- Negative 41/100
- Event
- Earnings
- Published
- 14 Jul 2026 21:13
- Source
- TradingView
Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates
Kestra Medical Technologies, Ltd. (KMTS) reported a Q4 loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a $0.59 loss, marking a -13.56% surprise. However, the company surpassed revenue estimates, posting $28.64 million, exceeding the consensus by 8.05
- Tone
- Negative 42/100
- Event
- Earnings
- Published
- 14 Jul 2026 21:10
- Source
- Market source
Earnings Flash (KMTS) Kestra Medical Technologies Posts Fiscal Q4 Per-Share Loss $0.67, vs. FactSet Est of Loss $0.59
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:06
- Source
- marketscreener.com
Kestra's up-to-$200M facility includes $50M for acquisitions
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 20:05
- Source
- Stock Titan
Kestra says ASSURE system protected 18,000 patients in FY26
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 20:01
- Source
- Stock Titan
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Kestra Medical Technologies (Nasdaq: KMTS) reported strong financial results for the fourth quarter and fiscal year ended April 30, 2026, with revenue increasing by 66% and 59% respectively, and significant gross margin expansion. The company's ASSURE® system protected 18,000 pat
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:13
- Source
- GlobeNewswire
Kestra Medical (Nasdaq: KMTS) adds $200M loan as revenue surges 59%
Kestra Medical Technologies (KMTS) secured a five-year senior secured term loan facility of up to $200 million with Pharmakon Advisors, with the initial Tranche A of $75 million funding on July 10, 2026. The company reported significant revenue growth for fiscal year 2026, reachi
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 14 Jul 2026 20:13
- Source
- Stock Titan
Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
Kestra Medical Technologies has secured up to $200 million in non-dilutive financing through a five-year term loan facility with Pharmakon Advisors, LP. This financing strengthens Kestra's balance sheet, reduces its cost of capital, and provides significant flexibility to invest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 20:13
- Source
- The Manila Times
Kestra Medical secures $75M loan facility with Pharmakon
Kestra Medical Technologies has secured a five-year term loan facility of up to $200 million with funds managed by Pharmakon Advisors, LP. This financing includes an initial $75 million tranche, with additional tranches available based on revenue milestones or for acquisitions. T
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 20:13
- Source
- Investing.com
Press Release: Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
Kestra Medical Technologies has secured up to $200 million in non-dilutive financing from a fund managed by leading global investment firm Carlyle. This significant funding will support Kestra's growth, expand its commercial efforts for the Assure® Wearable Cardioverter Defibrill
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 20:12
- Source
- Moomoo
Earnings To Watch: Kestra Medical Technologies Ltd (KMTS) Reports Q4 2026 Result
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 13:17
- Source
- Market source
Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 13 Jul 2026 09:24
- Source
- DirectorsTalk Interviews
ETFs Investing in Kestra Medical Technologies Ltd. Stocks
This article lists various ETFs that currently hold stocks of Kestra Medical Technologies Ltd. (KMTS). It provides a table detailing each ETF's market value, weight, issuer, management style, focus, expense ratio, AUM, price change percentage, relative volume, and 3-year NAV tota
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 20:41
- Source
- TradingView
KMTS Q4'25 Earnings: revenue estimate is 26.48M USD
Kestra Medical Technologies, Ltd. (KMTS) is scheduled to release its Q4'25 earnings on July 14, before market open. The company anticipates revenues of $26.48 million USD and an EPS of -$0.59 for the quarter. This article provides a detailed look at past revenue and EPS figures,
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 11:10
- Source
- TradingView
KMTS - Kestra Medical Technologies Ltd Options
This article provides a detailed financial overview of Kestra Medical Technologies Ltd (KMTS), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and othe
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 03 Jul 2026 16:10
- Source
- Finviz
Kestra Medical (KMTS) CBO adds 227 ESPP shares, now holds 42,488
Kestra Medical Technologies' Chief Business Officer, Timothy P. Moran, purchased 227 shares of common stock through the company's 2025 Employee Stock Purchase Plan (ESPP) on June 30, 2026, at a price of $21.55 per share. This transaction, which was exempt under Rule 16b-3, increa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 21:09
- Source
- Stock Titan
Kestra Medical (KMTS) director and officer acquires 942 ESPP shares
Kestra Medical Technologies director and officer Traci S. Umberger acquired 942 shares of common stock through the company's Employee Stock Purchase Plan at $21.55 per share. This purchase, exempt under Rule 16b-3, brings Umberger's beneficial ownership to 162,802 shares, includi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 21:09
- Source
- Stock Titan
Kestra Medical Technologies to report Q4FY26 results on July 14
Kestra Medical Technologies, a wearable medical device and digital healthcare company, will announce its Q4FY26 financial results after the market closes on July 14. This will be followed by a conference call at 4:30 p.m. ET to discuss the results and performance metrics for the
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 04:27
- Source
- scanx.trade
Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14
Kestra Medical Technologies (Nasdaq: KMTS) announced it will report its fourth-quarter fiscal 2026 financial results after market close on Tuesday, July 14. The company will also host a conference call at 4:30 p.m. Eastern Time to discuss the results. A webcast of the call will b
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 02:39
- Source
- Market source